“We sup­port In­dia’s tar­get of TB elim­i­na­tion by 2025”

BioSpectrum (India) - - Q&A - Dr Man­beena Chawla man­beena.chawla@mmac­tiv.com

US-based lead­ing molec­u­lar di­ag­nos­tics com­pany, Cepheid Inc. (a wholly owned sub­sidiary of Dana­her) un­veiled its new­est con­fig­u­ra­tion in the GeneXpert fam­ily of sys­tems, the GeneXpert Edge, in In­dia re­cently. More than 1,200 Cepheid’s GeneXpert Sys­tems have been in­stalled in the last 2 years at var­i­ous Re­vised Na­tional Tu­ber­cu­lo­sis Con­trol Pro­gram (RNTCP) sites in the coun­try and more than 2.5 mil­lion car­tridges were supplied last year at var­i­ous cen­tres of Cen­tral TB Di­vi­sion (CTD). The GeneXpert Edge is ex­pected to be avail­able in In­dia later this year. In re­gard to this de­vel­op­ment, BioSpec­trum in­ter­acted with Peter Far­rell, Ex­ec­u­tive Vice Pres­i­dent, World­wide Com­mer­cial Op­er­a­tions, Cepheid and Jai Shankar Kr­ish­nan, Pres­i­dent and CEO, In­dia and South­east Asia, Dana­her to get more in­sights. Edited Ex­cerpts;

What are the ma­jor plans ahead re­gard­ing the launch of GeneXpert Edge in In­dia?

Peter Far­rell: GeneXpert Edge is a por­ta­ble, easy-touse test­ing sys­tem that brings test­ing closer to pa­tients with the goal to di­ag­nose the num­ber of miss­ing TB cases, en­abling a test and treat ap­proach in one visit. Cepheid is con­tin­u­ing to col­lab­o­rate with the RNTCP of the Gov­ern­ment of In­dia to ex­tend the reach in the pe­riph­eral cen­tres which be­comes sig­nif­i­cantly eas­ier with the introduction of GeneXpert Edge. We have al­ready ini­ti­ated the val­i­da­tion of GeneXpert Edge and are all set to launch in In­dia. The de­cen­tral­ized test will have the same qual­ity as the ones done with GeneXpert all across the coun­try, us­ing Xpert MTB/RIF a WHO pre­qual­i­fied test.

Tell us some­thing about the Make in In­dia ini­tia­tive

re­cently an­nounced by the com­pany.

Jai Shankar Kr­ish­nan: Cepheid is com­mit­ted to sup­port the gov­ern­ment’s tar­get of TB elim­i­na­tion by 2025 and is tak­ing sig­nif­i­cant steps to an­chor a lo­cal man­u­fac­tur­ing pres­ence for Xpert MTB/RIF. The com­pany has long been an ac­tive par­tic­i­pant in the global fight against TB and is bol­ster­ing that com­mit­ment be­hind the ‘Make In In­dia’ cam­paign to help ac­cel­er­ate the goal of a TB-free In­dia. Cepheid is cur­rently at an ad­vanced stage of fi­nal­iz­ing the lo­ca­tion for the In­dia man­u­fac­tur­ing site. To­day Dana­her has a strong man­u­fac­tur­ing foot­print in In­dia, thus part­ner­ing with the ex­ist­ing Dana­her sites is also be­ing eval­u­ated. The site would be ded­i­cated to the de­vel­op­ment of Xpert MTB/RIF test car­tridges to be­gin with. Once the site is fi­nal­ized, we will also work out de­tails for em­ploy­ment op­por­tu­ni­ties.

What key strate­gies are fol­lowed for the busi­ness growth in In­dia?

Peter Far­rell: We con­tinue to work closely with key gov­ern­ment depart­ments like the CTD and im­por­tant stake­hold­ers like WHO, The Union, FIND, CHAI, other NGOs and pri­vate part­ners to bring the coun­try best in class test­ing so­lu­tions. We have in­creased our in­vest­ment in In­dia over the years, first through dis­tri­bu­tion part­ner­ships, then by de­vel­op­ing a lo­cal or­gan­i­sa­tion with a di­rect Cepheid pres­ence and now es­tab­lish­ing a man­u­fac­tur­ing foot­print for our Xpert MTB/RIF test to fully sup­port the gov­ern­ment’s tar­get of TB elim­i­na­tion by 2025. Cepheid is also com­mit­ted to en­hanc­ing its pres­ence in In­dia by lo­cal­iz­ing many of its func­tions, and bring­ing to the In­dian mar­ket, prod­ucts cus­tom­ized to the lo­cal needs. We are cur­rently fo­cused on set­ting up our first man­u­fac­tur­ing fa­cil­ity in In­dia and will con­tinue to eval­u­ate fur­ther ex­pan­sion based on mar­ket re­quire­ments.

What per­cent of the com­pany’s global rev­enue is con­trib­uted by the life sci­ences & di­ag­nos­tic sec­tor in In­dia?

Jai Shankar Kr­ish­nan: In­dia is one of Dana­her’s fastest grow­ing re­gions. Cepheid is an in­te­gral part of Dana­her’s Life Sci­ences and Di­ag­nos­tics port­fo­lio. The global con­tri­bu­tion from Life Sci­ences and Di­ag­nos­tics plat­form is 38 per cent and the In­dia port­fo­lio also mir­rors the same.

Peter Far­rell, Ex­ec­u­tive Vice Pres­i­dent, World­wide Com­mer­cial Op­er­a­tions, Cepheid

Jai Shankar Kr­ish­nan, Pres­i­dent and CEO, In­dia and South­east Asia, Dana­her

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.